Compare NUCL & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | SLGL |
|---|---|---|
| Founded | 2023 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 247.1M |
| IPO Year | N/A | 2016 |
| Metric | NUCL | SLGL |
|---|---|---|
| Price | $9.43 | $72.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 323.3K | 32.3K |
| Earning Date | 05-22-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $6.96 |
| 52 Week High | $14.22 | $97.97 |
| Indicator | NUCL | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 50.63 |
| Support Level | $8.81 | $66.40 |
| Resistance Level | $12.29 | $81.54 |
| Average True Range (ATR) | 0.70 | 6.03 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 30.32 | 51.90 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds the rights to the mineable, measured and indicated uranium deposit in the United States, referred to as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated 37.73 million pounds of near-surface uranium and the adjacent Cordex Zone Eagle's SMR technology. Eagle's mission is to supply uranium to the growing nuclear energy industry and play a role in the global transition to clean, reliable, and affordable energy.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.